Trials / Completed
CompletedNCT05873907
A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants
A Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the safety, tolerability and immunogenicity profile of single and multiple dose administrations of AMG 592 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 592 | Administered as SC injection |
| OTHER | Placebo | Administered as SC injection |
Timeline
- Start date
- 2015-10-19
- Primary completion
- 2017-06-16
- Completion
- 2017-07-28
- First posted
- 2023-05-24
- Last updated
- 2023-05-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05873907. Inclusion in this directory is not an endorsement.